AU3374795A - Conjugates of vascular endothelial growth factor with targeted agents - Google Patents

Conjugates of vascular endothelial growth factor with targeted agents

Info

Publication number
AU3374795A
AU3374795A AU33747/95A AU3374795A AU3374795A AU 3374795 A AU3374795 A AU 3374795A AU 33747/95 A AU33747/95 A AU 33747/95A AU 3374795 A AU3374795 A AU 3374795A AU 3374795 A AU3374795 A AU 3374795A
Authority
AU
Australia
Prior art keywords
conjugates
growth factor
vascular endothelial
endothelial growth
targeted agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU33747/95A
Inventor
Graham A Fleurbaaij
Erwin Freund
L.L. Houston
Michael P Nova
Barbara A Sosnowski
Kimberly D Victor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Selective Genetics Inc
Original Assignee
Selective Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Selective Genetics Inc filed Critical Selective Genetics Inc
Publication of AU3374795A publication Critical patent/AU3374795A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0042—Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Botany (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU33747/95A 1994-08-29 1995-08-29 Conjugates of vascular endothelial growth factor with targeted agents Abandoned AU3374795A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US441979 1982-11-15
US29796194A 1994-08-29 1994-08-29
US297961 1994-08-29
US44197995A 1995-05-16 1995-05-16
PCT/US1995/010973 WO1996006641A1 (en) 1994-08-29 1995-08-29 Conjugates of vascular endothelial growth factor with targeted agents

Publications (1)

Publication Number Publication Date
AU3374795A true AU3374795A (en) 1996-03-22

Family

ID=26970393

Family Applications (1)

Application Number Title Priority Date Filing Date
AU33747/95A Abandoned AU3374795A (en) 1994-08-29 1995-08-29 Conjugates of vascular endothelial growth factor with targeted agents

Country Status (2)

Country Link
AU (1) AU3374795A (en)
WO (1) WO1996006641A1 (en)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037329A (en) * 1994-03-15 2000-03-14 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
JPH11505805A (en) * 1995-05-16 1999-05-25 プリズム ファーマシューティカルズ，インコーポレイテッド Compositions containing nucleic acids and ligands for therapeutic treatment
GB9601640D0 (en) * 1996-01-26 1996-03-27 Cancer Res Campaign Tech Ligand directed enzyme prodrug therapy
ATE206059T1 (en) * 1996-06-24 2001-10-15 Selective Genetics Inc HEPARIN-COATED MEDICAL DEVICES FOR INTRAVENOUS USE CONTAINING HEPARIN-BINDING GROWTH FACTOR CONJUGATES
CN1181422A (en) * 1996-10-31 1998-05-13 上海市肿瘤研究所 Gene transfer carrier structured by polypeptide in conjunction with growth factor receptor
US6485942B1 (en) 1997-02-14 2002-11-26 Genentech, Inc. Variants of vascular endothelial cell growth factor having altered pharmacological properties, and recombinant methods of production
US6395707B1 (en) 1997-02-14 2002-05-28 Genentech, Inc. Methods of treatment utilizing variants of vascular endothelial cell growth factor
EP1005355A4 (en) * 1997-04-15 2002-07-17 Radix Organization Inc Method of treating gastrointestinal ulcers and compositions therefor
US6777534B1 (en) 1997-12-09 2004-08-17 Children's Medical Center Corporation Peptide antagonists of vascular endothelial growth factor
AU757554B2 (en) * 1998-02-11 2003-02-27 Bracco International B.V. Angiogenesis targeting molecules
JP3002725B2 (en) * 1998-06-19 2000-01-24 工業技術院長 Pharmaceutical composition comprising fibroblast growth factor-related peptide
CA2374050A1 (en) * 1999-05-20 2000-11-30 Scios Inc. Vascular endothelial growth factor dimers
US6475796B1 (en) 1999-05-20 2002-11-05 Scios, Inc. Vascular endothelial growth factor variants
JP2003519670A (en) * 2000-01-12 2003-06-24 ライト サイエンシーズ コーポレイション New treatments for eye diseases
US6506365B1 (en) 2000-09-25 2003-01-14 Baxter Aktiengesellschaft Fibrin/fibrinogen binding conjugate
GB0028991D0 (en) * 2000-11-28 2001-01-10 Univ College Of London Treatment of varicose veins
JP4541645B2 (en) 2001-04-12 2010-09-08 インペリアル・イノベイションズ・リミテッド Diagnosis and treatment of type I cancer
CU23178A1 (en) * 2002-04-15 2006-09-22 Ct Ingenieria Genetica Biotech ANTIANGIOGEN ACTIVE ACTIVE IMMUNOTHERAPY
GB0209896D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
GB0213878D0 (en) * 2002-06-17 2002-07-31 Protherics Plc Use
WO2004096254A2 (en) * 2003-05-02 2004-11-11 Xpression Antibody Therapeutics, Inc. Transferrin conjugates for tumor treatment
US7601341B2 (en) 2003-06-05 2009-10-13 Research Development Foundation Vascular endothelial growth factor fusion constructs used to inhibit osteoclastogenesis
EP1635764A4 (en) * 2003-06-17 2009-10-21 Roger G Harrison Conjugate for the specific targeting of anticancer agents to cancer cells and production thereof
US7893244B2 (en) 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
WO2006110813A2 (en) 2005-04-12 2006-10-19 Intradigm Corporation Composition and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases
GB0718843D0 (en) 2007-09-26 2007-11-07 Cancer Rec Tech Ltd Materials and methods relating to modifying the binding of antibodies
US8895701B2 (en) 2008-01-05 2014-11-25 Sloan-Kettering Institute For Cancer Research Peptide-conjugated oligonucleotide therapeutic and method of making and using same
WO2009089186A2 (en) * 2008-01-05 2009-07-16 Sloan-Kettering Institute For Cancer Research Peptide-conjugated oligonucleotide therapeutic and method of making and using same
TWI394580B (en) 2008-04-28 2013-05-01 Halozyme Inc Super fast-acting insulin compositions
KR20170102050A (en) 2008-05-27 2017-09-06 젠자임 코포레이션 Peptide analogs of alpha-melanocyte stimulating hormone
EP2334826A4 (en) 2008-09-12 2012-01-25 Cancer Res Initiative Foundation Method of detection and diagnosis of oral and nasopharyngeal cancers
KR101778317B1 (en) 2009-08-13 2017-09-13 얀센 백신스 앤드 프리벤션 비.브이. Antibodies against human respiratory syncytial virus(rsv) and methods of use
AU2010290989B2 (en) 2009-09-03 2016-05-19 Cancer Research Technology Limited CLEC14A inhibitors
GB0918383D0 (en) 2009-10-20 2009-12-02 Cancer Rec Tech Ltd Prognostic,screening and treatment methods and agents for treatment of metastasis and inflammation
BR112012031638B1 (en) 2010-07-09 2021-01-12 Janssen Vaccines & Prevention B.V. anti-rsv antibody or antigen binding fragment thereof, multivalent antibody, pharmaceutical composition, use of antibody or antigen binding fragment, method of detecting rsv infection, and isolated nucleic acid
US20140023589A1 (en) 2011-02-09 2014-01-23 Cancer Research Technology Limited Frmd4a antagonists and their uses
US20130011378A1 (en) 2011-06-17 2013-01-10 Tzung-Horng Yang Stable formulations of a hyaluronan-degrading enzyme
WO2012174480A2 (en) 2011-06-17 2012-12-20 Halozyme, Inc. Continuous subcutaneous insulin infusion methods with a hyaluronan degrading enzyme
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
GB201115529D0 (en) 2011-09-08 2011-10-26 Imp Innovations Ltd Antibodies, uses and methods
SG11201405553YA (en) 2012-03-08 2014-11-27 Halozyme Inc Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
EP2735874A1 (en) 2012-11-21 2014-05-28 Fundación Para La Investigación Biomédica Del Hospital Universitario Puerta De Hierro Methods of diagnosing and therapeutic agents for use in the treatment of prostate cancer
AU2014318545A1 (en) 2013-09-12 2016-03-24 Halozyme, Inc. Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
GB201322583D0 (en) 2013-12-19 2014-02-05 Alligator Bioscience Ab Antibodies
US20160340394A1 (en) 2014-01-27 2016-11-24 Molecular Templates, Inc. De-immunized shiga toxin a subunit effector polypeptides for applications in mammals
EP3102245B1 (en) 2014-02-05 2021-09-08 Molecular Templates, Inc. Methods of screening, selecting, and identifying cytotoxic recombinant polypeptides based on an interim diminution of ribotoxicity
EP3116904B1 (en) 2014-03-11 2020-05-06 Molecular Templates, Inc. Proteins comprising amino-terminal proximal shiga toxin a subunit effector regions and cell-targeting immunoglobulin-type binding regions capable of specifically binding her2/neu/erbb2
ES2723774T3 (en) 2014-03-11 2019-09-02 Molecular Templates Inc Proteins comprising binding regions, effector regions of the Shiga toxin subunit A and signal motifs of localization of carboxy terminal endoplasmic reticulum
CN106573031B (en) 2014-04-15 2021-05-28 加利福尼亚大学董事会 Double-ended pegylated integrin-binding peptides and methods of use thereof
CN113831416A (en) 2014-06-11 2021-12-24 分子模板公司 Shiga toxin a subunit effector polypeptides resistant to protease cleavage and cell targeting molecules comprising the same
GB201501004D0 (en) 2015-01-21 2015-03-04 Cancer Rec Tech Ltd Inhibitors
CN108064247B (en) 2015-02-05 2022-06-03 分子模板公司 Multivalent CD20 binding molecules comprising Shiga toxin A subunit effector region and enriched compositions thereof
GB201503438D0 (en) 2015-02-27 2015-04-15 Ucl Business Plc Antibodies
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
WO2018106895A1 (en) 2016-12-07 2018-06-14 Molecular Templates, Inc. Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
GB201706472D0 (en) 2017-04-24 2017-06-07 Cancer Res Tech Ltd Tumour-targeting peptide variants
JP2021506260A (en) 2017-12-15 2021-02-22 ジュノー セラピューティクス インコーポレイテッド Anti-CCT5 binding molecule and how to use it
GB201908591D0 (en) 2019-06-14 2019-07-31 Ucl Business Plc Methods for cancer diagnosis
WO2021102445A1 (en) 2019-11-24 2021-05-27 Molecular Templates, Inc. Uses of cd20-binding molecules and additional therapeutic agents
AU2020397803C1 (en) * 2019-12-06 2023-05-11 Regeneron Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
GB202009217D0 (en) 2020-06-17 2020-07-29 Ucl Business Ltd Methods for detecting and predicting breast cancer
GB202009220D0 (en) 2020-06-17 2020-07-29 Ucl Business Ltd Methods for detecting and predicting cancer
GB202009222D0 (en) 2020-06-17 2020-07-29 Ucl Business Plc Methods for detecting and predicting cancer
GB202017985D0 (en) 2020-11-16 2020-12-30 Ucl Business Ltd Methods for assessing vaginal microbiota community type
US20220195050A1 (en) 2020-12-16 2022-06-23 Molecular Templates, Inc. Clinical methods for use of a pd-l1-binding molecule comprising a shiga toxin effector
EP4355780A1 (en) 2021-06-18 2024-04-24 Alligator Bioscience AB Novel combination therapies and uses thereof
GB202116412D0 (en) 2021-11-15 2021-12-29 Sola Diagnostics Gmbh Methods for detecting and predicting breast cancer
WO2023247050A1 (en) 2022-06-23 2023-12-28 Alligator Bioscience Ab Combination therapies
GB202210965D0 (en) 2022-07-27 2022-09-07 Alligator Bioscience Ab Novel dosages
GB202210957D0 (en) 2022-07-27 2022-09-07 Alligator Bioscience Ab Novel dosages
GB202215115D0 (en) 2022-10-13 2022-11-30 Univ Nottingham VEGF antibodies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5332671A (en) * 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
DE69204990T2 (en) * 1991-01-03 1996-05-15 Salk Inst For Biological Studi MITOTOXIN FOR TREATMENT OF VESSEL DAMAGE.
EP0646174A1 (en) * 1992-06-16 1995-04-05 The Whittier Institute For Diabetes And Endocrinology Recombinant production of saporin-containing proteins
AU687727B2 (en) * 1992-10-28 1998-03-05 Genentech Inc. Vascular endothelial cell growth factor antagonists
AU7475694A (en) * 1993-08-02 1995-02-28 Prizm Pharmaceuticals, Inc. Monogenous preparations of cytotoxic conjugates
CA2185671A1 (en) * 1994-03-15 1995-09-21 Prizm Pharmaceuticals, Inc. Heparin-binding growth factors for gene therapy and anterior eye disorders

Also Published As

Publication number Publication date
WO1996006641A1 (en) 1996-03-07

Similar Documents

Publication Publication Date Title
AU3374795A (en) Conjugates of vascular endothelial growth factor with targeted agents
AU5439998A (en) Vascular endothelial growth factor
EP1062319A4 (en) Vascular endothelial growth factor 2
AU673995B2 (en) Vascular stent
AU7458596A (en) Vascular stent
AU2583399A (en) Variants of the angiogenic factor vascular endothelial cell growth factor: vegf
AU6086596A (en) Stent having varied amounts of structural strength along its length
AU7621794A (en) Vascular prostheses
AU3976397A (en) Scented undergarments
AU1448595A (en) Prostatic drug-delivery catheter
AU8572698A (en) Urinary catheter
AU1531599A (en) Medical article with adhered antimicrobial metal
AU2002252631A1 (en) Vascular endothelial growth factor 2
AU3202895A (en) Hollow smokable article
AU7297498A (en) Body support garment
AU5023300A (en) Vascular endothelial growth factor variants
WO2002083850A8 (en) Vascular endothelial growth factor 2
AU5025096A (en) Hollow stent
AU2741597A (en) Flowerpot and associated attachments
AU6473594A (en) Disposable undergarment
EP0873348A4 (en) Human vascular endothelial growth factor 3
AU2315797A (en) Promotion of regeneration of organized tissues
AU6472594A (en) Disposable undergarment
AU1830195A (en) Prostatic growth factor
AU3581195A (en) Absorbent article